MCID: HND002
MIFTS: 51

Hand, Foot and Mouth Disease

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Hand, Foot and Mouth Disease

MalaCards integrated aliases for Hand, Foot and Mouth Disease:

Name: Hand, Foot and Mouth Disease 12 74 43 15 17
Vesicular Stomatitis and Exanthem 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10881
ICD9CM 34 074.3
MeSH 43 D006232
NCIt 49 C128439
SNOMED-CT 67 266108008
ICD10 32 B08.4
UMLS 71 C0018572

Summaries for Hand, Foot and Mouth Disease

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Human coxsackievirus A16 or has material basis in Human enterovirus 71, which are transmitted by contaminated fomites, and transmitted by contact with nose and throat secretions, saliva, blister fluid and stool of infected persons. The infection has symptom fever, has symptom poor appetite, has symptom malaise, has symptom sore throat, has symptom painful sores in the mouth, and has symptom skin rash on the palms of the hands and soles of the feet.

MalaCards based summary : Hand, Foot and Mouth Disease, also known as vesicular stomatitis and exanthem, is related to exanthem and aseptic meningitis, and has symptoms including fever, poor appetite and sore throat. An important gene associated with Hand, Foot and Mouth Disease is SCARB2 (Scavenger Receptor Class B Member 2), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Mannitol and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Hand, foot, and mouth disease (HFMD) is a common infection caused by a group of viruses. It typically... more...

Related Diseases for Hand, Foot and Mouth Disease

Diseases related to Hand, Foot and Mouth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 352)
# Related Disease Score Top Affiliating Genes
1 exanthem 31.8 IL6 IL10 IFNG
2 aseptic meningitis 31.7 SCARB2 IL10 IFNG
3 encephalitis 31.5 TLR3 IL6 IL10 DDX58
4 poliomyelitis 31.4 SCARB2 IL10 IFNG
5 erythema multiforme 31.0 IL6 IL13 IFNG
6 meningoencephalitis 31.0 TLR3 IL6 IL10
7 chickenpox 30.9 TLR3 IL6 IL10 IFNG
8 dermatitis 30.9 IL6 IL13 IL10 IFNG
9 myocarditis 30.9 TLR4 TLR3 IL6 IL10 IFNG
10 stomatitis 30.8 TLR4 IL6 IL10 IFNG DDX58
11 chorioretinitis 30.8 IL6 IL10 IFNG
12 acute transverse myelitis 30.7 IL6 IL10
13 viral encephalitis 30.7 TLR3 IL6 IL10 DDX58
14 aphthous stomatitis 30.7 TLR4 IL6 IL10 IFNG
15 herpangina 30.6 TLR7 TLR4 TLR3 IL6 IL10 IFNG
16 bronchopneumonia 30.5 TLR4 IL6 IL10
17 graft-versus-host disease 30.5 IL6 IL10 IFNG
18 chlamydia 30.4 TLR4 IL6 IL10 IFNG
19 cellulitis 30.4 IL6 IL10 IFNG
20 purpura 30.4 IL6 IL10 IFNG
21 posterior uveitis 30.4 IL6 IL13 IFNG
22 herpes simplex 30.3 TLR3 OAS1 IL6 DDX58
23 endocarditis 30.3 IL6 IL10 IFNG
24 mumps 30.3 TLR3 IL6 IL10 IFNG
25 appendicitis 30.2 TLR4 IL6 IL10 IFNG
26 diarrhea 30.2 TLR4 IL6 IL13 IL10 IFNG
27 respiratory failure 30.2 TLR4 IL6 IL13 IL10
28 tetanus 30.2 IL6 IL13 IL10 IFNG
29 hepatitis a 30.2 TLR4 TLR3 IL10 IFNG
30 rhinitis 30.1 TLR4 IL6 IL13 IL10 IFNG
31 gaucher's disease 30.1 SCARB2 IL6 GBA
32 dermatitis, atopic 30.1 TLR4 TLR3 IL6 IL13 IL10 IFNG
33 meningitis 30.1 TLR4 S100B IL6 IL13 IL10 IFNG
34 measles 30.1 TLR7 TLR4 TLR3 OAS1 IL6 IFNG
35 tonsillitis 30.0 TLR4 TLR3 IL6 IL10 IFNG
36 viral hepatitis 29.9 TLR4 TLR3 IL6 IL10 IFNG
37 skin disease 29.8 S100B IL6 IL13 IL10 IFNG DDX58
38 plague 29.7 TLR4 TLR3 SCARA3 IL6 IL10 DDX58
39 autoimmune disease 29.6 IL6 IL13 IL10 IFNG C4A
40 bronchiolitis 29.4 TLR7 TLR4 TLR3 IL6 IL13 IL10
41 viral infectious disease 29.4 TLR7 TLR4 TLR3 OAS1 IL6 IL13
42 mouth disease 28.9 TLR7 TLR4 TLR3 SCARB2 SCARA3 S100B
43 pulmonary edema 10.8
44 cytokine deficiency 10.5
45 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.5
46 spotted fever rickettsiosis 10.5 IL10 IFNG
47 hyperglycemia 10.5
48 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL6 IL13
49 b-cell growth factor 10.4 IL6 IFNG
50 myoclonus 10.4

Graphical network of the top 20 diseases related to Hand, Foot and Mouth Disease:



Diseases related to Hand, Foot and Mouth Disease

Symptoms & Phenotypes for Hand, Foot and Mouth Disease

Symptoms:

12
  • fever
  • poor appetite
  • sore throat
  • malaise
  • painful sores in the mouth
  • skin rash on the palms of the hands

GenomeRNAi Phenotypes related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

26 (show all 32)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-113 9.89 C4A C4B
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.89 C4A C4B
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-137 9.89 C4A C4B
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-182 9.89 SCARA3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 9.89 C4A C4B
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.89 SCARA3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.89 C4A C4B
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-4 9.89 SCARA3
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 9.89 ANKRD17
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.89 ANKRD17
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-98 9.89 C4A C4B
12 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.77 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.77 C4A C4B
14 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.77 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.77 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.77 TLR4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.77 IL10
18 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.77 C4A C4B IL10
19 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.77 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.77 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.77 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.77 TLR4
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.77 C4A C4B
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.77 IL10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.77 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.77 C4A C4B
27 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.77 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.77 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.77 IL10 TLR4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.77 C4A C4B
31 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.77 IL10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.77 IL10

MGI Mouse Phenotypes related to Hand, Foot and Mouth Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 ANKRD17 C4B DDX58 GBA IFNG IL10
2 hematopoietic system MP:0005397 10.15 C4B DDX58 FUBP1 GBA IFNG IL10
3 cardiovascular system MP:0005385 10.1 ANKRD17 C4B FUBP1 GBA IFNG IL10
4 immune system MP:0005387 10.03 C4B DDX58 FUBP1 GBA IFNG IL10
5 mortality/aging MP:0010768 9.8 ANKRD17 C4B DDX58 FUBP1 GBA IFNG
6 liver/biliary system MP:0005370 9.76 C4B DDX58 FUBP1 GBA IFNG IL10
7 respiratory system MP:0005388 9.23 FUBP1 GBA IFNG IL10 IL13 IL6

Drugs & Therapeutics for Hand, Foot and Mouth Disease

Drugs for Hand, Foot and Mouth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
2
Ribavirin Approved Phase 4 36791-04-5 37542
3 Immunoglobulins, Intravenous Phase 4
4 Antibodies, Blocking Phase 4
5 Anti-Infective Agents Phase 4
6 Antiviral Agents Phase 4
7 Antimetabolites Phase 4
8 Antibodies Phase 4
9 Immunoglobulins Phase 4
10 Vaccines Phase 4
11 Immunologic Factors Phase 4
12
Ibuprofen Approved Phase 2 15687-27-1 3672
13
Acetaminophen Approved Phase 2 103-90-2 1983
14
Sucralfate Approved Phase 2 54182-58-0
15
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
16
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9 24083
17
Aluminum sulfate Approved Phase 2 10043-01-3
18
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
19 Pharmaceutical Solutions Phase 2
20 Anti-Inflammatory Agents Phase 2
21 Analgesics, Non-Narcotic Phase 2
22 Antipyretics Phase 2
23 Cyclooxygenase Inhibitors Phase 2
24 Antirheumatic Agents Phase 2
25 Anti-Inflammatory Agents, Non-Steroidal Phase 2
26 Gastrointestinal Agents Phase 2
27 Hormones Phase 2
28 Anesthetics Phase 2
29 Retinol palmitate Phase 2
30 retinol Phase 2
31 Anti-Arrhythmia Agents Phase 2
32 Tocolytic Agents Phase 2
33 Anticonvulsants Phase 2
34 Analgesics Phase 2
35 Calcium, Dietary Phase 2
36 calcium channel blockers Phase 2
37 Antacids Phase 2
38 Anti-Ulcer Agents Phase 2
39 Adjuvants, Immunologic Phase 2
40
Calcium Nutraceutical Phase 2 7440-70-2 271
41
Suramin Investigational Phase 1 145-63-1 5361
42 Anthelmintics Phase 1
43 Antiprotozoal Agents Phase 1
44 Antiparasitic Agents Phase 1
45
Prednisolone phosphate Approved, Vet_approved 302-25-0
46
Methylprednisolone Approved, Vet_approved 83-43-2 6741
47
Methylprednisolone hemisuccinate Approved 2921-57-5
48
Prednisolone Approved, Vet_approved 50-24-8 5755
49 Prednisolone acetate Approved, Vet_approved 52-21-1
50 Grape Approved

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months Unknown status NCT02889497 Phase 4
2 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Unknown status NCT03296410 Phase 4
3 The Safety, Immune Persistence and Consistency of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) Unknown status NCT02999828 Phase 4
4 A Opened,Randomized and Controlled Trial to Evaluate the Immunity and Safety of Sequential Vaccination of Two Different Commercial EV71 Inactived Vaccines in Healthy Infants Aged 6-35 Months Completed NCT03873740 Phase 4
5 A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd. Completed NCT03278132 Phase 4
6 Effectiveness and Safety of Inactivated EV71 Vaccine (Human Diploid Cell) in 6-71 Months Children: an Open-label Controlled Phase Ⅳ Clinical Study Completed NCT03001986 Phase 4
7 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine Completed NCT03274102 Phase 4
8 Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients Completed NCT02328651 Phase 4 Ribavirin plus Xiao'er jiebiao oral liquid;Ribavirin
9 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
10 Multiple Centers, Randomized, and Control Trail on the Immunogenicity and Safety of the Simultaneously Vaccination of Inactivated Enterovirus 71 Vaccine (EV71) and Seasonal Influenza Vaccine(SIV) Recruiting NCT04133584 Phase 4
11 Study on Immunogenicity of Inactivated Enterovirus 71 (EV71) Vaccine (Human Diploid Cell, KMB-17) in Large-scale Healthy Children in China Active, not recruiting NCT03240744 Phase 4
12 Phase Ⅳ Clinical Trial, to Evaluate the Efficacy of the Enterovirus 71 (EV71) Inactivated Vaccine and Its Correlation With EV71 Antibody Level Active, not recruiting NCT03903926 Phase 4
13 A Phase IV Clinical Trial for Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71: A Multicenter, Case-control Study. Enrolling by invitation NCT03582761 Phase 4
14 Three Batches Consistency, Immunity Duration and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China Not yet recruiting NCT03893747 Phase 4
15 A Multicentered, Double - Blind, Randomized, and Placebo - Controlled Clinical Trial With Inactivated Enterovirus Type 71 (EV71) Vaccines Completed NCT01507857 Phase 3
16 A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months Completed NCT01508247 Phase 3
17 Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine: A Double-blind, Randomized and Controlled Trial Completed NCT01636245 Phase 3
18 A Phase III Clinical Trial With Randomized, Double-blinded, Controlled Design as Well as Bridging Design to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Children Aged 36-71 Months Completed NCT03909074 Phase 3
19 A Phase III Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants and Children Completed NCT01569581 Phase 3
20 An Open-Label, Dose-Finding, Phase II Study to Evaluate the Immunogenicity and Safety of the Bioreactor-generated EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 2 to 35 Months Old Unknown status NCT03268083 Phase 2
21 Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Unknown status NCT03241030 Phase 2 Sucralfate;Acetaminophen;Ibuprofen
22 An Open-label, Dose-finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old Completed NCT02777411 Phase 2
23 A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Magnesium Sulfate for the Management of Severe Hand, Foot and Mouth Disease With Autonomic Nervous System Dysregulation in Vietnamese Children. Completed NCT01940250 Phase 2 Magnesium Sulphate;Sterile water
24 A Phase II Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants Completed NCT01512706 Phase 2
25 A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01399853 Phase 2
26 A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Completed NCT01734408 Phase 2
27 Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults Completed NCT01376479 Phase 1
28 A Phase Ia Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children Completed NCT01267903 Phase 1
29 A Phase Ib Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01313715 Phase 1
30 A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants Completed NCT01391494 Phase 1
31 A Blind, Randomized and Placebo-controlled Clinical Trial With Inactivated Enterovirus Type 71 Vaccines in Healthy Children. Completed NCT01273246 Phase 1
32 A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of CJ-40010 After Administration in Healthy Subjects Recruiting NCT04182932 Phase 1
33 A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium in Healthy Chinese Adults Recruiting NCT03804749 Phase 1 suramin sodium
34 A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01182025 Xiyanping Injection;Xiyanping Injection with western medicine
35 A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01175915
36 A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease Unknown status NCT01145664 Herbal concentrate-granules plus western therapy;Reduning Injection plus western therapy;Western therapy
37 Long Term Outcomes of EV71 Central Nervous System Infection Unknown status NCT00172393
38 Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study Completed NCT01769794 Western therapy;JET;Placebo(for JET)
39 An Open-labelled, Multicentered, Follow-up Study for a Phase III, Efficacy Trial to Evaluate the Two-year Efficacy, Safety, and Immune Persisitence of Inactivated Enterovirus Type 71 (EV71) Vaccine Completed NCT02001233
40 A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Severe Type of Hand, Foot, and Mouth Disease Completed NCT01554930 Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge);Xiyanping injection plus western therapy
41 A Clinical Trial to Evaluate the Effectiveness and Safety of Chinese Medicine in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Completed NCT01182532 TCM Syndrome Differentiation and Treatment
42 Phase IV, Open-labelled, Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine Completed NCT03281174
43 A Prospective Cohort Study Evaluating Prognostic Indicators and Sequelae Following Severe Hand Foot and Mouth Disease Completed NCT02066714
44 Study on Dynamic Changes of the Maternal Anti-EV71 and Anti-CVA16 Antibody Levels in Infants and Young Children Completed NCT01255124
45 Do Traditional or Flavored Tongue Depressors Make for Easier Posterior Completed NCT03095183
46 Evaluation of Different Methods for Rapid Diagnosis of Meningitis in Assiut University Hospital Not yet recruiting NCT03759470

Search NIH Clinical Center for Hand, Foot and Mouth Disease

Cochrane evidence based reviews: hand, foot and mouth disease

Genetic Tests for Hand, Foot and Mouth Disease

Anatomical Context for Hand, Foot and Mouth Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Hand, Foot and Mouth Disease:

19
Skin

MalaCards organs/tissues related to Hand, Foot and Mouth Disease:

40
Skin, T Cells, Testes, Brain, Tongue, Heart, B Cells

Publications for Hand, Foot and Mouth Disease

Articles related to Hand, Foot and Mouth Disease:

(show top 50) (show all 2091)
# Title Authors PMID Year
1
Enterovirus 71 induces neural cell apoptosis and autophagy through promoting ACOX1 downregulation and ROS generation. 61
32434419 2020
2
Exosomes cloak the virion to transmit Enterovirus 71 non-lytically. 61
31885311 2020
3
Epitope Peptide Amphiphile-Based Nanofiber as an Effective Vaccine for Viral Infectious Diseases. 61
32331099 2020
4
Quantifying the risk of hand, foot, and mouth disease (HFMD) attributable to meteorological factors in East China: A time series modelling study. 61
32361359 2020
5
Virological investigation of genetic variation of enterovirus type 71 in hand, foot and mouth disease. 61
32537012 2020
6
Acarbose, as a potential drug, effectively blocked the dynamic metastasis of EV71 from the intestine to the whole body. 61
32004757 2020
7
Prevalence and Management of Severe Hand, Foot, and Mouth Disease in Xiangyang, China from 2008-2013. 61
32543714 2020
8
Influence of temperature and humidity on hand, foot, and mouth disease in Guangzhou, 2013-2017. 61
32527174 2020
9
Effect of heat-clearing and detoxifying Chinese medicines combined with conventional therapy on mild hand, foot, and mouth disease with fever: An individual patient data meta-analysis. 61
32501994 2020
10
Short-term effects of meteorological factors, air pollution, and sunspot on childhood hand, foot, and mouth disease in Tianjin, China: a new time series regression, 2014-2018. 61
32577970 2020
11
Vitamin D receptor gene methylation in patients with hand, foot, and mouth disease caused by enterovirus 71. 61
32556549 2020
12
Immunomodulatory effects of platelets on the severity of hand, foot, and mouth disease infected with enterovirus 71. 61
32516798 2020
13
Assessing the vaccine effectiveness for hand, foot, and mouth disease in Guangzhou, China: a time-series analysis. 61
32530733 2020
14
Temperature and hand, foot and mouth disease in California: An exploratory analysis of emergency department visits by season, 2005-2013. 61
32278924 2020
15
The Epidemiological and Clinical Characteristics of Hand, Foot, and Mouth Disease in Hangzhou, China, 2016 to 2018. 61
32146823 2020
16
Seasonal Distribution and Meteorological Factors Associated with Hand, Foot, and Mouth Disease among Children in Xi'an, Northwestern China. 61
32157992 2020
17
Transcriptome sequencing analysis of SH-SY5Y cells infected with EV71 reveals the potential neuropathic mechanisms. 61
32220619 2020
18
Acute enterovirus infections significantly alter host cellular DNA methylation status. 61
31927072 2020
19
Muscle destruction caused by coxsackievirus A10 in gerbils: construction of a novel animal model for antiviral evaluation. 61
32553610 2020
20
The modification effect of the diurnal temperature range on the exposure-response relationship between temperature and pediatric hand, foot and mouth disease. 61
32208268 2020
21
The Function and Mechanism of Enterovirus 71 (EV71) 3C Protease. 61
32556480 2020
22
Inhibition of Enterovirus 71 by Selenium Nanoparticles Loaded with siRNA through Bax Signaling Pathways. 61
32548434 2020
23
Lack of effective home quarantine: The cause of the continuing prevalence of hand, foot, and mouth disease in China? 61
32473816 2020
24
Association of gene polymorphisms of CD55 with susceptibility to and severity of hand, foot, and mouth disease caused by enterovirus 71 in the Han Chinese population. 61
32470169 2020
25
Epidemiological and clinical characteristics of severe hand-foot-and-mouth disease (HFMD) among children: a 6-year population-based study. 61
32460823 2020
26
Hirsutism, Amphetamines, COVID-19 Viral Shedding, Hand-Foot-and-Mouth Disease. 61
32352260 2020
27
Hirsutism, Amphetamines, COVID-19 Viral Shedding, Hand-Foot-and-Mouth Disease. 61
32412216 2020
28
Coxsackievirus A10 causing hand-foot-and-mouth disease in Uruguay. 61
32081777 2020
29
WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines. 61
32418797 2020
30
Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications. 61
32424333 2020
31
Epidemiology of Hand, Foot, and Mouth Disease Before and After the Introduction of Enterovirus 71 Vaccines in Chengdu, China, 2009-2018. 61
32433221 2020
32
Sodium Copper Chlorophyllin Is Highly Effective against Enterovirus (EV) A71 Infection by Blocking Its Entry into the Host Cell. 61
32233455 2020
33
Atypical hand-foot-mouth disease in Belém, Amazon region, northern Brazil, with detection of coxsackievirus A6. 61
32302950 2020
34
Exosomes from EV71-infected oral epithelial cells can transfer miR-30a to promote EV71 infection. 61
31958204 2020
35
Erythema multiforme-like hand, foot, and mouth disease in an immunocompetent adult: a case report. 61
31742678 2020
36
Epidemiological and aetiological characteristics of hand, foot, and mouth disease in Sichuan Province, China, 2011-2017. 61
32273569 2020
37
[Therapeutic effect of acupuncture on dysphagia in children with severe hand foot and mouth disease]. 61
32275368 2020
38
Chromogranin A provides additional prognostic information in children with severe hand, foot, and mouth disease: A prospective observational study. 61
32109626 2020
39
Integration of a Kalman filter in the geographically weighted regression for modeling the transmission of hand, foot and mouth disease. 61
32276607 2020
40
Spatial heterogeneity of the association between temperature and hand, foot, and mouth disease risk in metropolitan and other areas. 61
31954246 2020
41
Development of a multivalent enterovirus subunit vaccine based on immunoinformatic design principles for the prevention of HFMD. 61
32247566 2020
42
Coxsackievirus A16 in a 1-Day-Old Mouse Model of Central Nervous System Infection Shows Lower Neurovirulence than Enterovirus A71. 61
32359633 2020
43
Mechanism for the lethal effect of enterovirus A71 intracerebral injection in neonatal mice. 61
31857694 2020
44
Interaction between PHB2 and Enterovirus A71 VP1 Induces Autophagy and Affects EV-A71 Infection. 61
32276428 2020
45
Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections. 61
32321526 2020
46
The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple Enteroviruses. 61
32075935 2020
47
Co-circulation of coxsackieviruses A-6, A-10, and A-16 causes hand, foot, and mouth disease in Guangzhou city, China. 61
32264839 2020
48
Genome Sequence of a Human Coxsackievirus A6 Strain Isolated from a Severe Hand, Foot, and Mouth Disease Case in Qingdao, China, in 2017. 61
32327512 2020
49
Cardiopulmonary failure in children infected with Enterovirus A71. 61
32299443 2020
50
Genetic characterization of VP1 of coxsackieviruses A2, A4, and A10 associated with hand, foot, and mouth disease in Vietnam in 2012-2017: endemic circulation and emergence of new HFMD-causing lineages. 61
32008121 2020

Variations for Hand, Foot and Mouth Disease

Expression for Hand, Foot and Mouth Disease

Search GEO for disease gene expression data for Hand, Foot and Mouth Disease.

Pathways for Hand, Foot and Mouth Disease

Pathways related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 TLR7 TLR4 TLR3 S100B OAS1 IL6
2
Show member pathways
12.81 TLR7 TLR4 TLR3 OAS1 IL6 IL10
3
Show member pathways
12.78 IL6 IL13 IL10 IFNG C4A
4 12.72 TLR3 OAS1 IL6 IFNG DDX58
5
Show member pathways
12.65 TLR7 TLR4 TLR3 OAS1 IL6 IFNG
6
Show member pathways
12.53 TLR4 IL6 IL13 IL10 IFNG
7 12.42 TLR7 TLR3 OAS1 IL10 IFNG DDX58
8
Show member pathways
12.25 TLR4 TLR3 IL6 IFNG
9
Show member pathways
12.2 TLR7 TLR4 TLR3 IL6
10
Show member pathways
12.19 OAS1 IL6 IL13 IL10 IFNG
11 12.17 TLR4 IL6 IL10 IFNG
12
Show member pathways
12.12 TLR7 TLR4 IL6 IFNG
13 12.09 TLR7 TLR4 TLR3 IL6 IFNG
14 12.06 IL6 IL13 IL10 C4B C4A
15
Show member pathways
11.94 TLR7 TLR4 TLR3 IL13
16 11.82 IL10 C4B C4A
17 11.82 TLR4 IL6 IL10 IFNG
18 11.8 TLR4 IL6 IFNG
19 11.75 TLR7 TLR4 TLR3
20 11.73 IL6 IL13 IFNG
21 11.71 IL13 IL10 IFNG
22 11.66 TLR7 IL6 IL10 IFNG
23
Show member pathways
11.61 TLR7 TLR4 TLR3 IL6 IFNG
24 11.48 IL6 IL13 IL10
25 11.44 IL13 IL10 IFNG
26 11.37 TLR4 IL6 IL10 IFNG
27 11.31 IL6 IL10 IFNG
28 11.28 TLR4 IL6 IL10
29 11.23 TLR4 IL6 IL10 C4B C4A
30 11.22 IL6 IL13 IFNG
31
Show member pathways
11.13 TLR7 TLR4 TLR3 IL6 IL10 IFNG
32 11.12 IL13 IL10 IFNG
33 10.92 IL6 IL13 IL10 IFNG
34 10.73 IL6 IL13

GO Terms for Hand, Foot and Mouth Disease

Cellular components related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.4 TLR3 SCARA3 S100B MIR576 MIR221 IL6
2 endosome membrane GO:0010008 9.26 TLR7 TLR4 TLR3 SCARB2

Biological processes related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.08 TLR7 TLR4 TLR3 OAS1 DDX58 C4B
2 immune response GO:0006955 10.04 TLR7 TLR4 OAS1 IL6 IL13 IL10
3 positive regulation of gene expression GO:0010628 10 TLR4 TLR3 IL6 IL13 IFNG FUBP1
4 defense response to bacterium GO:0042742 9.97 TLR4 TLR3 IL10 ANKRD17
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.95 TLR4 TLR3 S100B ANKRD17
6 inflammatory response GO:0006954 9.95 TLR7 TLR4 TLR3 IL6 IL13 C4B
7 negative regulation of inflammatory response GO:0050728 9.92 MIR221 IL13 IL10 GBA
8 response to virus GO:0009615 9.9 TLR3 OAS1 IFNG DDX58
9 positive regulation of inflammatory response GO:0050729 9.87 TLR7 TLR4 TLR3 IFNG
10 cellular response to mechanical stimulus GO:0071260 9.86 TLR7 TLR4 TLR3 IL13
11 defense response to virus GO:0051607 9.85 TLR7 TLR3 OAS1 IL6 IFNG DDX58
12 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.84 TLR7 TLR4 TLR3
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 MIR221 IL6 IL13 IFNG
14 response to glucocorticoid GO:0051384 9.83 S100B IL6 IL10
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 TLR7 TLR4 TLR3
16 toll-like receptor signaling pathway GO:0002224 9.81 TLR7 TLR4 TLR3
17 positive regulation of interleukin-6 secretion GO:2000778 9.8 TLR4 IFNG DDX58
18 negative regulation of interleukin-6 production GO:0032715 9.79 TLR4 IL10 GBA
19 positive regulation of JAK-STAT cascade GO:0046427 9.78 MIR221 IL6 IL10
20 positive regulation of interferon-beta production GO:0032728 9.77 TLR4 TLR3 DDX58
21 positive regulation of interleukin-12 production GO:0032735 9.75 TLR4 TLR3 IFNG
22 positive regulation of macrophage activation GO:0043032 9.72 TLR4 IL13 IL10
23 I-kappaB phosphorylation GO:0007252 9.7 TLR7 TLR4 TLR3
24 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 TLR4 IL10 IFNG
25 positive regulation of chemokine biosynthetic process GO:0045080 9.68 TLR3 IFNG
26 macrophage activation GO:0042116 9.68 TLR4 IL13
27 positive regulation of interferon-alpha production GO:0032727 9.68 TLR4 DDX58
28 toll-like receptor 3 signaling pathway GO:0034138 9.67 TLR3 SCARA3
29 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.67 MIR221 IL10
30 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.65 TLR4 TLR3
31 positive regulation of apoptotic cell clearance GO:2000427 9.64 C4B C4A
32 detection of virus GO:0009597 9.64 TLR3 DDX58
33 positive regulation of interferon-alpha biosynthetic process GO:0045356 9.62 TLR7 TLR3
34 microglial cell activation GO:0001774 9.62 TLR7 TLR3 IL13 IFNG
35 positive regulation of interferon-beta biosynthetic process GO:0045359 9.61 TLR7 TLR4 TLR3
36 regulation of dendritic cell cytokine production GO:0002730 9.58 TLR4 TLR3
37 positive regulation of interleukin-8 production GO:0032757 9.56 TLR7 TLR4 TLR3 DDX58
38 positive regulation of chemokine production GO:0032722 9.46 TLR7 TLR4 TLR3 IL6
39 positive regulation of interleukin-6 production GO:0032755 9.35 TLR7 TLR4 TLR3 IL6 DDX58
40 innate immune response GO:0045087 9.28 TLR7 TLR4 TLR3 S100B OAS1 DDX58

Molecular functions related to Hand, Foot and Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 TLR7 TLR4 TLR3 SCARB2 SCARA3 S100B
2 cytokine activity GO:0005125 9.46 IL6 IL13 IL10 IFNG
3 double-stranded RNA binding GO:0003725 8.92 TLR7 TLR3 OAS1 DDX58

Sources for Hand, Foot and Mouth Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....